Biomedical Advanced Research and Development Authority – Biasly

Biomedical Advanced Research and Development Authority Follow

HOPO Therapeutics, Inc.: HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

Radiation

HOPO Therapeutics, Inc.: HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy...

FinanzNachrichten.de
Oct 28, 2024

Somewhat Liberal

default thumbnail

Radiation

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

Financial Post
Oct 28, 2024

Somewhat Liberal

Spectral MD Sees 2022 Loss Ahead of Market Expectations

Clinical trial

Spectral MD Sees 2022 Loss Ahead of Market Expectations

MarketWatch
Jan 16, 2023

Center